Skip to content

Repeated Voluntary Drug Intoxication (IMVr): Characterization of a New Addictive Behavior by Clinical Phenotyping and Functional Imaging

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02889042
Acronym
Phenot IMVr
Enrollment
1
Registered
2016-09-05
Start date
2016-07-19
Completion date
2016-07-19
Last updated
2019-12-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alcoholic, Volunteers, Volunteers Repeated Drug Poisoning

Brief summary

France is one of the European countries with the highest rate of death by suicide, more than 10 400 deaths each year, about 16 people out of 100 000. Although suicide mortality rate tends to fall between 1987 and 2008 the number of suicide attempts (TS) against observed by an upward trend between 2005 and 2010. However, the most important predictor of death by suicide remains the TS. Now these are primarily TS Poisoning Drug-Volunteer (IMV), especially benzodiazepines. These IMV, there have been 16% recurrence in the past year and 21% at 4 years among hospitalized patients. Or a Health Barometer 2005 survey showed that 58% of respondents with a TS over the last 12 months had not been hospitalized. This type of acting out, especially the repeated IMV (IMVr) is underestimated epidemiologically because it is an unknown phenomenon and too little screened by health professionals.

Detailed description

The IMVr constitute severe behavior disorder, chronic and costly given the multiple prescriptions, hospital admissions, including emergencies, and repeated treatment failures, in the absence of specific treatment of psychopathological problematic background. Indeed many arguments lead to evoke the existence of a functioning underlying addictive type, rather than a problem of suicide, especially from the second recurrence (often characterized by low lethality and suicidal intentionality). This impulsive behavior and / or compulsive repeatedly would not simply the consequence of a pharmacological benzodiazepine dependence (it is also not systematic), but would demonstrate a similar operation to that of behavioral addictions. Furthermore, a preliminary study has shown that this type of behavior was not limited to a BPD personality type, since it is mainly found pathological personalities depressive and avoidant types. In this context it is urgent to make an accurate characterization of these patients IMVr because the integration of the addictive dimension in their care will adapt strategies psychotherapeutic, pharmacological, and the terms of issue of psychotropic and especially benzodiazepines .

Interventions

OTHERMRI and biological assessment

performing a MRI and a biological assessment

Sponsors

University Hospital, Grenoble
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Will be offered for study subjects that meet the following criteria: * Man or woman hospitalized (e) in the aftermath of a IMV: * History of at least 2 for the IMV group IMVr * First suicide attempt high intentionality (SIS score\> 20/30) for group IMVS * Man or woman with alcohol dependence according to DSM-IV-TR, in the aftermath of withdrawal (outpatient or inpatient) for the alcohol group * Man or woman free from any addictive disorder, suicidal or mood for the control group And all of the following criteria: * Age greater than or equal to 18 and less than or equal to 60 years * Informed consent in writing signed by the patient * Person affiliated to the social security or beneficiary of such a scheme

Exclusion criteria

For IMVS Group: * Have a history of scarification or addictive disorder (behavioral or product) In the alcohol group: * TS present history For all patients, presenting at least one of the following criteria: * Age less than 18 years, over 60 years. * acute or chronic delusional disorder. * Cognitive impairment or impeding the reading comprehension quizzes. * secondary pathologies at a stroke. * Denial of participation. * Contraindications to MRI. * Subjects with clinically significant gastrointestinal, renal, hepatic, endocrine, cardiovascular or respiratory (especially persistent asthma) which can prevent stay of 60 min in MRI without being hindered. * No participant to another pharmacological study. * unauthorized treatments: all psychotropic treatments (except anti-anxiety treatments benzodiazepine average duration of action and antihistamine), baclofen and other treatment can modify vasoreactivity fMRI. * Coagulation disorders against-indicating blood. * People under guardianship

Design outcomes

Primary

MeasureTime frame
Comparison of local measurements of changes in the BOLD (Blood Oxygenation Level Dependent) based on visual stimuli by anatomical and functional MRI15 days of the passage to the act

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026